Novo Nordisk - Search News

Novo Nordisk to cap insulin prices in Minnesota settlement

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

CBS Minnesota on MSN · 2d

Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

KARE-TV Minneapolis-St. Paul o… · 2d

Novo Norodisk caps insulin prices at $35 for Minnesotans

If you rely on insulin, you will be able to buy Novo Nordisk's products for $35 per month due to a settlement announced Monday.

Novo Nordisk’s Ozempic Gets FDA Approval

Reuters on MSN · 1d

US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

The Wall Street Journal on MSN · 1d

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

CNBC on MSN · 1d

FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

4don MSN

Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

6d

Novo Nordisk next-gen shot shows 22% weight loss in early results

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Moderna, Novo Nordisk slammed for breaching UK drug marketing code yet again

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

12d

Is Novo Nordisk Stock a Buy?

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

2d

Novo Nordisk Hit With Suit for Underwhelming CagriSema Trial (1)

A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...

6don MSN

Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

9don MSN

Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

5don MSN

The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week

Here are some of the major companies whose stocks moved on the week’s news.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results